147 related articles for article (PubMed ID: 8435807)
1. Prognostic significance of bone metastases in patients with metastatic prostate cancer.
Yamashita K; Denno K; Ueda T; Komatsubara Y; Kotake T; Usami M; Maeda O; Nakano S; Hasegawa Y
Cancer; 1993 Feb; 71(4):1297-302. PubMed ID: 8435807
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density for patients with bone metastasis of prostate cancer: a preliminary report.
Tanaka H; Furukawa Y; Fukunaga K; Fukunaga M
Adv Exp Med Biol; 1992; 324():217-31. PubMed ID: 1492619
[TBL] [Abstract][Full Text] [Related]
3. Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2).
Jørgensen T; Müller C; Kaalhus O; Danielsen HE; Tveter KJ
Eur Urol; 1995; 28(1):40-6. PubMed ID: 8521893
[TBL] [Abstract][Full Text] [Related]
4. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between extent of bone metastases and effect of endocrine therapy evaluated with bone scintigraphy in stage D2 prostatic cancer].
Tanaka M; Murakami S; Akimoto S; Masai M; Shimazaki J
Nihon Hinyokika Gakkai Zasshi; 1992 Jul; 83(7):1036-42. PubMed ID: 1507721
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy.
Rigaud J; Tiguert R; Le Normand L; Karam G; Glemain P; Buzelin JM; Bouchot O
J Urol; 2002 Oct; 168(4 Pt 1):1423-6. PubMed ID: 12352409
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
8. Study on the distribution features of bone metastases in prostate cancer.
Wang C; Shen Y
Nucl Med Commun; 2012 Apr; 33(4):379-83. PubMed ID: 22293499
[TBL] [Abstract][Full Text] [Related]
9. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
10. Distribution of bony metastases in prostatic carcinoma.
Cumming J; Hacking N; Fairhurst J; Ackery D; Jenkins JD
Br J Urol; 1990 Oct; 66(4):411-4. PubMed ID: 2224435
[TBL] [Abstract][Full Text] [Related]
11. Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer.
Kanoh Y; Ohtani N; Mashiko T; Ohtani S; Nishikawa T; Egawa S; Baba S; Ohtani H
Anticancer Res; 2001; 21(1B):551-6. PubMed ID: 11299802
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features and prognosis in 104 colorectal cancer patients with bone metastases].
Hong RX; Lin QJ; Luo J; Dai Z; Wang WN
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):787-91. PubMed ID: 24378104
[TBL] [Abstract][Full Text] [Related]
13. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
14. Is there a favorable subset of patients with prostate cancer who develop oligometastases?
Singh D; Yi WS; Brasacchio RA; Muhs AG; Smudzin T; Williams JP; Messing E; Okunieff P
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):3-10. PubMed ID: 14697414
[TBL] [Abstract][Full Text] [Related]
15. Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate.
Rana A; Chisholm GD; Khan M; Sekharjit SS; Merrick MV; Elton RA
Br J Urol; 1993 Dec; 72(6):933-6. PubMed ID: 8306158
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
Ost P; Decaestecker K; Lambert B; Fonteyne V; Delrue L; Lumen N; Ameye F; De Meerleer G
Prostate; 2014 Feb; 74(3):297-305. PubMed ID: 24395565
[TBL] [Abstract][Full Text] [Related]
17. Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy.
Wong KW; Ma WK; Wong CW; Wong MH; Tsang CF; Tsu HL; Ho KL; Yiu MK
Hong Kong Med J; 2016 Apr; 22(2):106-15. PubMed ID: 26635306
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma.
Aprikian AG; Cordon-Cardo C; Fair WR; Zhang ZF; Bazinet M; Hamdy SM; Reuter VE
J Urol; 1994 Apr; 151(4):914-9. PubMed ID: 8126824
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Heidenreich A; Pfister D; Porres D
J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
[TBL] [Abstract][Full Text] [Related]
20. Skeletal response to clodronate in prostate cancer with bone metastases.
Fernández-Conde M; Alcover J; Aaron JE; Ordi J; Carretero P
Am J Clin Oncol; 1997 Oct; 20(5):471-6. PubMed ID: 9345330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
